CURRICULUM VITAE
`
`
`Name: Richard E. Gregg, M.D.
`
`Email:
` richard.gregg1@gmail.com
`
`Telephone: 609-439-8203
`
`Address:
`7 Linden Lane
`
`
`
`Pennington, NJ 08534
`
`Education:
`
`
`
`Internal Medicine, 1979
`Endocrinology and Metabolism, 1981
`
`
`
`Brief Chronology of Employment:
`
`Intern, Internal Medicine, Strong Memorial Hospital,
`1976 - 1977
`Rochester, NY
`
`
`1977 - 1978 Resident, Internal Medicine, Strong Memorial Hospital,
`
`
`Rochester, NY
`1978 - 1982 Clinical Associate, Molecular Disease Branch,
`
`
`NHLBI, NIH, Bethesda, MD
`1982 - 1984 Medical Staff Fellow, Molecular Disease Branch,
`
`
`NHLBI, NIH, Bethesda, MD
`1984 - 1988 Senior Investigator, Molecular Disease Branch,
`
`
`NHLBI, NIH, Bethesda, MD
`1988 - 1996 Executive Director, Department of Metabolic Diseases,
`
`
`Bristol-Myers Squibb Pharmaceutical Research Institute,
`
`
`Princeton, NJ
`1996-1998 Vice President, Metabolic Diseases, Drug Discovery
`
`
`Bristol-Myers Squibb Pharmaceutical Research Institute,
`
`
`Princeton, NJ
`1999-2001 Vice President, Metabolic and Cardiovascular Drug Discovery
`
`
`Bristol-Myers Squibb Pharmaceutical Research Institute,
`
`
`Princeton, NJ
`2001-2007 Vice President, Clinical Discovery
`
`
`Bristol-Myers Squibb Pharmaceutical Research Institute,
`
`
`Princeton, NJ
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Feb. 1970 - B.S. Biochemistry, Iowa State University
`Aug. 1971 - M.S. Biochemistry, Iowa State University
`June 1976 - M.D. Stanford University
`
`
`
`
`Board Certification:
`
`1 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Curriculum Vitae: Gregg, Richard E.
`
`Military Service:
`Commissioned Corps, United States Public Health Service, 1978 – 1988
`
`
`
`Page 2
`
`
`Societies:
`American Association for the Advancement of Science
`American College of Physicians
`American Heart Association, Council on Atherosclerosis
`American Diabetes Association
`
`
`
`
`
`Honors:
`Undergraduate
`Phi Kappa Phi (Scientific Honorary Society), Iowa State University, 1970
`Award for the Most Outstanding Student in One's Major Field (Biochemistry),
`Iowa State University, 1970
`Graduated with Honors and Distinction, Iowa State University, 1970
`
`
`
`
`
`
`
`Medical School
`It was the policy of Stanford University School of Medicine during the time of my
`enrollment not to give scholastic honors or awards.
`
`Western Student Medical Research Forum Award for Meritorious Research,
`1975 and 1976
`
`
`
`
`
`
`
`
`
`
`
`
`Professional
`Fellow of the Council on Atherosclerosis, American Heart Association, 1982
`Fellow of the American College of Physicians, 1985
`Pfizer Traveling Lectureship, Montreal Clinical Research Institute, 1985
`Visiting Professor, Shandong Medical College, Jinan, China, 1986
`
`Member of Board of Directors
`American Federation for Aging Research (1999-2005)
`Robert Wood Johnson University Hospital at Hamilton (2001-present)
`
`2 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`
`
`Page 3
`
`
`
`
`Curriculum Vitae: Gregg, Richard E.
`Research Experience:
`1969 - 1971 Mechanism of protein biosynthesis in eukaryotic organisms
`
`
`1974 - 1976 Metabolism of triglycerides in experimentally induced acute and
`chronic uremia
`1978 - 1988 Metabolism of lipoproteins and apolipoproteins in human subjects
`1988 - 2001 Led Drug Discovery activities for BMS in Cardiovascular and
`Metabolic Diseases; regulation of lipoprotein metabolism; regulation of
`carbohydrate and fatty acid metabolism; regulation of weight; aging
`and chronic degenerative diseases; atherosclerosis and vessel wall
`biology; thrombosis. Twenty-five compounds nominated for clinical
`development; seven compounds still in clinical development.
`Led all Exploratory Development and Clinical Pharmacology activities
`for BMS; Phase I&II, mechanism of action, and proof of concept
`studies; Clinical Pharmacology studies in all phases; development and
`use of novel biomarkers; pharmacogenetic and genomic studies;
`developed modeling and simulation capabilities.
`
`2001-2007
`
`
`BMS Special Activities:
`
`1995 - 1998 Led the Exploratory Development working groups for squalene
`synthase inhibitors and for MTP inhibitors
`Drug Discovery Productivity Initiative
`
`Member of Task Force
`
`Responsible for writing Drug Discovery Handbook
`Change leader; responsible for planning and rolling out
`Productivity Initiative to all of Drug Discovery
`Selected to participate in the inaugural CEO’s Forum (two day meeting
`with CEO for high potential mid-level executives)
`Led the team that developed the vision for Applied Genomics and
`initiated the efforts for BMS in genetics/genomics/biotechnology
`Core member of Drug Discovery Redesign Task Force
`Member of Clinical Development Redesign Task Force
`Developed vision, organizational structure, and processes for Clinical
`Discovery
`Led the team to develop structure and processes for Exploratory
`Development Teams (strategic planning and development
`coordination for Exploratory Development compounds)
`Responsible for selection and assimilation of members of DuPont
`Pharma’s Drug Metabolism and Clinical Pharmacology Departments
`into BMS Clinical Discovery
`Led the team to develop the structure and processes for Exploratory
`Clinical Research Teams (exploratory development clinical operations)
`Led the team to coordinate closure of the Wilmington Drug Discovery
`site and assimilate employees into other BMS sites and projects
`Led the Drug Discovery Strategic Portfolio and Staffing team (set
`strategies and processes for BMS Drug Discovery)
`2002 - 2007 Co-leader of Exploratory Development Operating Committee
`(governance body for compounds in Exploratory Development)
`
`1996
`
`
`
`
`1997
`
`1998
`
`2001
`
`2002
`
`
`
`
`
`
`3 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 4
`
`Curriculum Vitae: Gregg, Richard E.
`
`
`Member Brand Development Operating Committee (governance body
`for Full Development)
`Member Institute Executive Committee
`Member Medical Review Committee (most senior medical review
`group for BMS)
`Responsible for approving First in Human studies
`
`
`
`
`
`
`
`
`
`
`
`4 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Curriculum Vitae: Gregg, Richard E.
`
`
`
`Page 5
`
`
`BIBLIOGRAPHY
`
`
`1. Gregg, R.E. and Heintz, R.L.: The inhibition of eukaryotic aminoacyl tranferase I by
`chartreusin. Arch. Biochem. and Biophys. 152:451-456, 1972.
`
`
`2. Gregg, R.E., Mondon, C.E., Reaven, E.P., and Reaven, G.M.: Effect of acute uremia on
`triglyceride kinetics in the rat. Metabolism 25:1557-1566, 1976.
`
`
`3. Gregg, R.E., Diamond, A., and Reaven, G.M.: Effect of chronic uremia and
`glucocorticoid therapy on triglyceride kinetics in rat. Metabolism 26:875-882, 1977.
`
`
`4. Gregg, R.E., Zech, L.A., Schaefer, E.J., and Brewer, H.B., Jr.,: Type III
`hyperlipoproteinemia: Defective metabolism of an abnormal apolipoprotein E.
`Science 211:584-586, 1981.
`
`
`5. Ghiselli, G., Schaefer, E.J., Zech, L.A., Gregg, R.E., Brewer, H.B. Jr.: Increased
`prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J. Clin. Invest.
`70:474-477, 1982.
`
`
`6. Ghiselli, G., Gregg, R.E., Zech, L.A , Schaefer, E.J, Brewer, H.B., Jr.: Phenotype study
`of apolipoprotein E isoforms in hyperlipoproteinemia patients. The Lancet ii:405-407,
`1982.
`
`
`7.
`
`Schaefer, E.J, Zech, L.A., Gregg, R.E., Brewer, H.B., Jr.: Metabolism of high density
`lipoproteins. In: Proceedings of the USA-USSR First Lipoprotein Symposium. U.S.
`Department of Health and Human Services, NIH Publication No. 83-1966,
`Washington, D.C., U.S. Government Printing Office, pp. 105-122, 1982.
`
`
`8. Goldstein, D.S., Dionne, R., Sweet, J., Gracely, R., Brewer, H.B., Jr., Gregg, R.E., and
`Keiser, H.R.: Circulatory, plasma catecholamine, cortisol, lipid and psychological
`responses to a real-life stress (Third molar extractions): Effects of diazepam sedation
`and of inclusions of epinepherine with the local anesthetic. Psychosomatic Medicine
`44:259-272, 1982.
`
`
`9.
`
`Brown, R.E., Gregg, R.E., and Hood, J.C.: Droperidol treatment of streptozocen-
`induced nausea and vomiting. Drug Intell. and Clin. Pharm. 16:775-776, 1982.
`
`
`10. Cogan, D.G., Chu, F.C., Barringer, J. and Gregg, R.E.: Maculo Halo Syndrome.
`Tr. Am. Ophth. Soc. 80:184-192, 1983.
`
`
`11. Gregg, R.E., Zech, L.A., and Brewer, H.B., Jr.: Apolipoprotein E alleles in severe
`hypertriglyceridemia. The Lancet 1:353, 1983.
`
`
`12. Gregg, R.E.: Molecular and metabolic defects. In: Type III hyperlipoproteinemia:
`Diagnosis, molecular defects, pathology, and treatment. Brewer, H.B., Jr., Moderator.
`Ann. Intern. Med. 98:628-632, 1983.
`
`5 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Curriculum Vitae: Gregg, Richard E.
`
`13. Meng, M.S., Gregg, R.E., Schaefer, E.J., Hoeg, J.M., and Brewer, H.B., Jr.: Presence of
`two forms of apolipoprotein B in patients with dyslipoproteinemia. J. Lipid Res.
`24:803-809, 1983.
`
`
`
`Page 6
`
`
`14. Brewer, H.B., Jr., Schaefer, E.J., Gregg, R.E., Osborne, J.C., Jr., and Zech, L.A.: Human
`plasma lipoproteins. In: Lipoprotein Metabolism and Therapy of Lipid Diseases G.
`Crepaldi, H. Greten, G. Schettler, and G. Baggio (eds.) Experta Medica, Amsterdam,
`pp. 3-11, 1983.
`
`
`15. Hoeg, J.M., Papadopoulos, N., Gregg, R.E., and Brewer, H.B., Jr.: Heterogeneity of
`lipoprotein electrophoretic patterns in type IIa hyperlipoproteinemia patients. Clin.
`Chem. 29:1459-1462, 1983.
`
`
`16. Hoeg, J.M., Osborne, J.C., Jr., Gregg, R.E., and Brewer, H.B., Jr.: Initial diagnosis of
`lipoprotein lipase deficiency in a 75-year-old man. Am. J. Med. 75:889-894, 1983.
`
`
`17. Gregg, R.E., Ghiselli, G., and Brewer, H.B., Jr.: Apolipoprotein EBethesda: A new
`variant of apolipoprotein E associated with type III hyperlipoproteinemia. J. Clin.
`Endo. Metab. 57:969-974, 1983.
`
`
`18. Gregg, R.E., Wilson, D., Rubalcaba, E., Ronan, R., and Brewer, H.B., Jr.:
`Immunoquantitation of apolipoprotein E. In: Proceedings of the workshop on
`apolipoprotein quantification. Lippel, K. (ed.) DHHS, NIH Pub. No. 83-1266. U.S.
`Government Printing Office, Washington, D.C., pp. 383-401, 1983.
`
`
`19. Brewer, H.B., Jr., Schaefer, E.J., Gregg, R.E., and Zech, L.A.: Current concepts in the
`structure, function, and metabolism of human plasma lipoproteins. In: Diabetes,
`obesity and hyperlipidemia II. G. Crepaldi, P.J. Lefebvre and D.J. Galton (eds.)
`Academic Press, Inc., New York, pp. 3-9, 1983.
`
`
`20. Bojanovski, D., Gregg, R.E., and Brewer, H.B., Jr: Tangier Disease: In vitro conversion
`of proapoA-ITangier to Mature apoA-ITangier. J.Biol. Chem. 259:6049-6051, 1984.
`
`
`21. Sprecher, D.L., Schaefer, E.J., Kent, K.M., Gregg, R.E., Zech, L.A., Hoeg, J.M.,
`McManus, B., Roberts, W.C., and Brewer, H.B., Jr.: Cardiovascular features of
`homozygous familial hypercholesterolemia. Am. J. Card. 54:20-30, 1984.
`
`
`22. Brewer, H.B., Jr., Gregg, R.E., Bojanovski, D., Law, S.W., and Zech, L.A.: Genetic
`disorders of HDL apolipoprotein metabolism. In: Clinical and Metabolic Aspects of
`High Density Lipoproteins. N.E. Miller and G.J. Miller (eds.) Elsevier Press,
`Amsterdam, pp. 275-287, 1984.
`
`
`23. Ghiselli, G., Gregg, R.E., and Brewer, H.B., Jr.: Apolipoprotein EBethesda: Isolation
`and partial characterization of a variant of human apolipoprotein E isolated from very
`low density lipoproteins. Biochem. Biophys. Acta. 794:333-339, 1984.
`
`6 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`
`
`Page 7
`
`Curriculum Vitae: Gregg, Richard E.
`
`24. Hoeg, J.M., Schaefer, E.J., Romano, C.A., Bou, E., Pikus, A.M., Zech, L.A., Bailey, K.R.,
`Gregg, R.E., Wilson, P.W., Sprecher, D.L., Grimes, A.M., Sebring, H.G., Ayres, E.J.,
`Jahn, C.E., and Brewer, H.B., Jr.: Neomycin and plasma lipoproteins in type II
`hyperlipoproteinemia. Clin. Pharm. and Therapeutics 36:555-565, 1984.
`
`
`25. Avigan, M.I., Ishak, K.G., Gregg, R.E., Hoofnagle, J.H.: Morphologic features of the
`liver in abetalipoproteinemia. Hepatology 4:1223-1226, 1984.
`
`
`26. Gregg, R.E., Zech, L.A., Schaefer, E.J., and Brewer, H.B., Jr.: Apolipoprotein E
`metabolism in normolipoproteinemic human subjects. J. Lipid Res. 25:1167-1176,
`1984.
`
`
`27. Fojo, S.S., Law, S.W., Sprecher, D.L., Gregg, R.E., Baggio, G., and Brewer, H.B., Jr.:
`Analysis of the apoC-II gene in apoC-II deficient patients. Biochem. Biophys. Res.
`Commun. 124:308-313, 1984.
`
`
`28. Hoeg, J.M., Maher, M.B., Bou, E., Zech, L.A., Bailey, K.R., Gregg, R.E., Sprecher, D.L.,
`Susser, J.K., Pikus, A.M., and Brewer, H.B., Jr: Combination use of neomycin and
`niacin normalizes the plasma lipoprotein concentrations in Type II
`hyperlipoproteinemia. Circulation 70:1004-1101, 1984.
`
`
`29. Brewer, H.B., Jr., Gregg, R.E., Hoeg, J.M., and Law, S.W.: The structure and function of
`the human plasma apolipoproteins and lipoproteins. In: Lipoproteins and Coronary
`Arterty Disease, J. Shephard, C.J. Packard, A.R. Loremer, T.D.V. Lawrie, H.G. Morgan,
`S.M. Brownlie (eds.) Blantyre Printing, Ltd., Glasgow, pp. 13-20, 1984.
`
`
`30. Bojanovski, D., Gregg, R.E., Ghiselli, G., Schaefer, E.J., Zech, L.A., and Brewer, H.B.,
`Jr.: Human apolipoprotein A-I isoprotein metabolism: proapoA-I conversion to
`mature apoA-I. J. Lipid Res. 26:185-193, 1985.
`
`
`31. Hoeg, J.M., Loriaux, L., Gregg, R.E., Green, W.R., and Brewer, H.B., Jr.: Impaired
`adrenal reserve in the Watanabe Heritable Hyperlipidemic Rabbit: Implications for
`LDL receptor function in steriodogenesis. Metabolism 34:194-197, 1985.
`
`
`32. Fong, B.S., Rodrigues, P.O., Salter, A.M., Yip, B.P., Depres, J.-P., Angel, A., and Gregg,
`R.E.: Characterization of high density lipoprotein binding to human adipocyte
`plasma membranes. J. Clin. Invest. 75:1804-1812, 1985.
`
`
`33. Hoeg, J.M., Demosky, S.J., Jr., Gregg, R.E.., Schaefer, E.J., and Brewer, H.B., Jr.:
`Hepatic receptors for low density lipoproteins and apolipoprotein E are genetically
`and physiologically distinct in man. Science 227:759-761, 1985.
`
`
`34. Lackner, K.J., Edge, S.B., Gregg, R.E., Hoeg, J.M., and Brewer, H.B., Jr.: Isoforms of
`apoA-II in human plasma and thoracic duct lymph: Identification of proapoA-II and
`sialic acid containing isoforms. J. Biol. Chem. 260:703-706, 1985.
`
`
`
`7 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 8
`
`Curriculum Vitae: Gregg, Richard E.
`35. Sprecher, D.L., Hoeg, J.M., Shaefer, E.J., Zech, L.A., Gregg, R.E., Lakatos, E., and
`Brewer, H.B., Jr.: The association of LDL receptor activity, LDL cholesterol level, and
`clinical course in homozygous familial hypercholesterolemia. Metabolism 34:294-299,
`1985.
`
`
`36. Hoeg, J.M., Demosky, S.J., Jr., Edge, S.B., Gregg, R.E., Osborne, J.C., Jr., and Brewer,
`H.B., Jr.: Characterization of a human hepatic receptor for high density lipoproteins.
`Arteriosclerosis 5:228-237, 1985.
`
`
`37. Gahl, W.A., Gregg, R.E., Hoeg, J.,M., and Fisher, E.: In vivo alteration of mutant
`human protein using the free thiol cysteamine. Am. J. Med. Genet. 20:409-417, 1985.
`
`
`38. Hoeg, J.M., Segal, P., Gregg, R.E., Chang, Y.S., Lindgren, F.T., Adamson, G.L., Frank,
`M., Rickman, C., and Brewer, H.B., Jr.: Characterization of plasma lipids and
`lipoproteins in patients with beta-2 glycoprotein I (apolipoprotein H) deficiency.
`Atherosclerosis 55:25-34, 1985.
`
`
`39. Hoeg, J.M., Maher, M.B., Bailey, K.R., Zech, L.A., Gregg, R.E., Sprecher, D.L., and
`Brewer, H.B., Jr: Effects of combination cholestryamine-neomycin treatment on
`plasma lipoprotein concentrations in Type II hyperlipoproteinemia. Am. J. Cardiol.
`55:1282-1286, 1985.
`
`
`40. Wichman, A., Buchthal, F., Pezeshkpour, G.H., and Gregg, R.E.: Peripheral
`neuropathy in abetalipoproteinemia. Neurology 35:1279-1289, 1985.
`
`
`41. Fink, I.J., Lee, M.A., and Gregg, R.E.: Radiographic and CT appearance of
`intraosseous xanthoma mimicking a malignant lesion. Brit. J. of Rad. 58:262-264, 1985.
`
`
`42. Wilson, P.F., Zech, L.A., Gregg, R.E., Schaefer, E.J., Hoeg, J.M., Sprecher, D.L., and
`Brewer, H.B., Jr.: Estimation of VLDL cholesterol in hyperlipidemia. Clin. Chim.
`Acta. 151:285-291, 1985.
`
`
`43. Brewer, H.B., Jr., Sprecher, D.L., Gregg, R.E., and Hoeg, J.M.: Risk factors for the
`development of premature cardiovascular disease. Adv. in Exp. Med. and Biol. 183:27-
`36, 1985.
`
`
`44. Brewer, H.B., Jr., Law, S.W., Gregg, R.E., and Hoeg, J.M.: Human plasma
`apolipoproteins: Genetics and role in lipoprotein metabolism. In: Diabetes, Obesity
`and Hyperlipidemias - III. G. Crepaldi et al (eds.) Elsevier Science Publishers B.V., pp
`31-35, 1985.
`
`
`45. Hoeg, J.M., Gregg, R.E., and Brewer, H.B., Jr.: An approach to the management of
`hyperlipoproteinemia. J. Am. Med. Assoc. 255:512-521, 1986.
`
`
`46. Gregg, R.E., and Brewer, H.B., Jr.: In vivo metabolism of apolipoprotein E in humans.
`In: Methods in Enzymology, J. Segrest and J. Albers, (eds.), 129:482-497, 1986.
`
`
`
`8 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`
`Curriculum Vitae: Gregg, Richard E.
`47. Anchors, J.M., Gregg, R.E., Law, S.W., and Brewer, H.B., Jr.: ApoE deficiency:
`markedly decreased levels of cellular apoE mRNA. Biochem. Biophs. Res. Comm.
`134:937-943, 1986.
`
`Page 9
`
`
`48. Gabelli, C., Gregg, R.E., Zech, L.A., Manzato, E., and Brewer, H.B., Jr: Abnormal low
`density lipoprotein metabolism in apolipoprotein E deficiency. J. Lipid. Res. 27:326-
`333, 1986.
`
`
`49. Gabelli, C., Stark, D.G., Gregg, R.E., and Brewer, H.B., Jr.: Separation of
`apolipoprotein B species by agarose-acrylamide gel electrophoresis. J. Lipid. Res.
`27:457-460, 1986.
`
`
`50. Brewer, H.B., Jr., Gregg, R.E., and Law, S.W.: Clinical disorders of lipoprotein
`metabolism. In: Monographs on Atherosclerosis, Vol. 14, A. Ventura, G. Crepaldi,
`(eds.) S. Karger AG, Basel, Switzerland. pp. 159-169, 1986.
`
`
`51. Gregg, R.E. and Brewer, H.B., Jr.: The role of apolipoprotein E in modulating the
`metabolism of apolipoprotein B-48 and apolipoprotein B-100 containing lipoproteins
`in humans. Adv. Exp. Med. Biol. 201:289-298, 1986.
`
`
`52. Brewer, H.B., Jr., Bojanovski, D., Gregg, R.E., and Law, S.W.: Recent studies on the
`metabolic defect in Tangier Disease. In: Human Apolipoprotein Mutants, C.R.
`Sirtori, A.V. Nichols, and G. Franceshini(eds.) Plenum Publishing, New York, pp. 129-
`132, 1986.
`
`
`53. Brewer, H.B., Jr., Anchors, M., Gregg, R.E., and Law, S.W.: Recent studies on the
`molecular defect in apolipoprotein E deficiency. In: Human Apolipoprotein Mutants,
`C.R. Sirtori, A.V. Nichols, and G. Franceshini (eds.) Plenum Publishing, New York,
`pp. 223-227, 1986.
`
`
`54. Hoeg, J.M., Maher, M.B., Zech, L.A., Bailey, K.R., Gregg, R.E., Lackner, K.J., Fojo, S.S.,
`Anchors, M.A., Bojanovski, M., Sprecher, D.L., and Brewer, H.B., Jr.: Effectiveness of
`mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
`Amer. J. Card. 57:933-939, 1986.
`
`
`55. Hoeg, J.M., Edge, S.B., Demosky, S.J., Jr., Staryl, T.E., Triche, T., Gregg, R.E., and
`Brewer, H.B., Jr.: Metabolism of low density lipoproteins by cultured hepatocytes
`from normal and homozygous familial hypercholesterolemic subjects. Biochem.
`Biophs. Acta. 876:646-657, 1986.
`
`
`56. Gregg, R.E., Connor, W.E., Lin, D.S., and Brewer, H.B., Jr.: Abnormal metabolism of
`shellfish sterols in a patient with sitosterolemia and xanthomatosis. J. Clin. Invest.
`77:1864-1872, 1986.
`
`
`57. Schaefer, E.J., Gregg, R.E., Ghiselli, G., Forte, T.M., Zech, L.A., and Brewer, H.B., Jr.:
`Familial apolipoprotein E deficiency. J. Clin. Invest. 78:1206-1219, 1986.
`
`
`
`9 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 10
`
`Curriculum Vitae: Gregg, Richard E.
`58. Gregg, R.E., Zech, L.A., Schaefer, E.J., Stark, D., Wilson, D., and Brewer, H.B., Jr.:
`Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78:815-
`821, 1986.
`
`
`59. Gregg, R.E., and Brewer, H.B., Jr.: Modulation of the metabolism of apolipoprotein B-
`48 and B-100 containing lipoproteins by apolipoprotein E. In: Atherosclerosis VII,
`N.H. Fridge and P.J. Nestel (eds.), Elsevier Science Publishers, pp. 335-339 1986.
`
`
`60. Lackner, K.J., Monge, J.C., Gregg, R.E., Hoeg, J.M., Triche, T.J., Law, S.W., and Brewer,
`H.B., Jr.: Analysis of the apolipoprotein B gene and mRNA in abetalipoproteinemia.
`J. Clin. Invest. 78:1707-1712, 1986.
`
`
`61. Brewer, H.B., Jr., Law, S.W., Gregg, R.E., and Hoeg, J.M.: Lipoproteins and
`Apolipoproteins: The Genetic Human Dyslipoproteinemias. In: Recent Advances in
`Arteriosclerosis Research. W.H. Hauss, R.W. Wissten, J. Gruennald (eds.)
`Westdeutscher Verlag, pp. 17-27, 1987.
`
`
`62. Wang, C.-S., Alaupovic, P., Gregg, R.E., and Brewer, H.B., Jr.: Studies on the
`mechanism of hypertriglyceridemia in Tangier Disease. Determination of plasma
`lipolytic activities, K1 values and apolipoprotein composition of the major lipoprotein
`density classes. Biochim. Biophy. Acta. 920:9-19, 1987.
`
`
`63. Gregg, R.E., Zech, L.A., Gabelli, C., Hoeg, J.M., and Brewer, H.B., Jr.: The role of
`apolipoprotein E and the low density lipoprotein receptor in modulating in vivo
`metabolism if apolipoprotein B containing lipoproteins. In: Cardiovascular Disease
`L.L. Gallo (ed.), Plenum Publishing, N.Y., N.Y., pp. 93-102, 1987.
`
`
`64. Bojanovski, M., Gregg, R.E., Wilson, D.M., and Brewer, H.B., Jr.: Semi-automated
`enzyme-linked immunosorbent assay (ELISA) for the quantification of apolipoprotein
`B using monoclonal antibodies. Clin. Chem. Acta. 170:271-280, 1987.
`
`
`65. Bojanovski, D., Gregg, R.E., Zech, L.A., Meng, M.S., Bishop, C., Ronan, R., Brewer,
`H.B., Jr.: Tangier Disease: the in vivo metabolism of proapolipoprotein A-I in Tangier
`disease. J. Clin. Invest. 80:1742-1747, 1987.
`
`
`66. Law, S.W., Monge, J.C., Lackner, K.J., Grant, S., Higuchi, K., Hospattanker, A.V.,
`Hoeg, J.M., Gregg, R.E., Lee, N., Sakaguchi, A., Naylor, S., and Brewer, H.B., Jr.:
`Human apolipoprotein B: Cloning and analysis of liver and intestinal mRNA and their
`expression in patients with abetalipoproteinemia. In: Cardiovascular Disease L.L.
`Gallo (ed.), Plenum Publishing, New York, pp. 21-32, 1987.
`
`
`67. Brewer, H. B., Jr., Gregg, R.E., Law, S.W., Hoeg, J.M., and Zech, L.A.: Human
`apolipoprotein A-I and A-II metabolism. In: Drugs Affecting Lipid Metabolism.
`Paoletti, R.: et al (eds.), Springer-Verlag, Berlin; Heidelberg, pp. 236-243, 1987.
`
`
`
`10 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 11
`
`Curriculum Vitae: Gregg, Richard E.
`68. Brewer, H.B., Jr., Law, S.W., Hoeg, J.M., and Gregg, R.E.: Overview of apolipoprotein
`B structure and metabolism. In: Proceedings of the Workshop on Lipoprotein
`Heterogeneity. K. Lippel (ed.), United States Government Printing
`Office, NIH Publication No. 87-2646, pp. 45-56, 1987.
`
`
`69. Gregg, R.E., Gabelli, C., and Brewer, H.B., Jr.: Regulation of the metabolism of
`apolipoprotein B containing lipoproteins by apolipoprotein E and the low density
`lipoprotein and remnant lipoprotein receptors. In: Proceedings of the Workshop on
`Lipoprotein Heterogeneity, K. Lippel (ed.), United States Government Printing Office,
`NIH Publication No. 87-2646, pp. 237-247, 1987.
`
`
`70. Davignon, J., Gregg, R.E., and Sing, C.F.: Apolipoprotein E polymorphism and
`atherosclerosis. Arteriosclerosis 8:1-21, 1988.
`
`
`71. Ross, R.S., Gregg, R.E., Law, S.W., Monge, J.C., Grant, S.M., Higuchi, K., Triche, T.J.,
`Jefferson, J., and Brewer, H.B., Jr.: Homozygous hypobetalipoproteinemia: a disease
`distinct from abetalipoproteinemia at the molecular level. J. Clin. Invest. 81:590-595,
`1988.
`
`
`72. Sprecher, D.L., Taam, L., Gregg, R.E., Fojo, S.S., Wilson, D.M., Kashyap, M.L., and
`Brewer, H.B., Jr.: Identification of an apoC-II variant (apoC-IIBethesda) in a kindred
`with apoC-III deficiency and type I hyperlipoproteinemia. J. Lipid Res. 29:273-278,
`1988.
`
`
`73. Gregg, R.E., Brewer, H.B., Jr.: The role of apolipoprotein E and lipoprotein receptors
`in modulating in vivo catabolism of apolipoprotein B containing lipoproteins in
`humans. Clin. Chem. 34:B28-32, 1988.
`
`
`74. Bojanovski, M., Gregg, R.E., Wilson, D.M., and Brewer, H.B., Jr.: Competitive enzyme-
`linked immunosorbent assay (ELISA) for the quantitation of apolipoprotein A-I using
`a monoclonal antibody. Clin. Chem. Acta 178:159-69, 1988.
`
`
`75. Benvenga, S., Gregg, R.E., and Robbins, J.R.: Binding of thyroid hormones to human
`plasma lipoproteins. J. Clin. Endocrin. Metab. 67:6-16, 1988.
`
`
`76. Fojo, S.S., Baggio, G., Gabelli, C., Higuchi, K., Bojanovski, M., Gregg, R.E., and Brewer,
`H.B., Jr.: Apolipoprotein C-II deficiency: Identification of a structural variant apoC-
`IIPadova. Biochem. Biophys. Res. Comm. 154:73-79, 1988.
`
`
`77. Fojo, S.S., Beisiegel, U., Beil, U., Higuchi, K., Bojanovski, M., Gregg, R.E., and Brewer,
`H.B., Jr.: A donor splice site mutation in the apoC-11 gene (apoC-II Hamburg) in a
`patient with apoC-II deficiency. J. Clin. Invest. 82:1489-1494, 1988.
`
`
`78. Fojo, S.S., Stalenhoef, A.F.H., Marr, K., Gregg, R.E., Ross, R.S., and Brewer, H.B., Jr.: A
`deletion mutation in the apoC-II gene (ApoC-IINijmegen) of a patient with a
`deficiency of apolipoprotein C-II. J. Biol. Chem. 263:17913-17916, 1988.
`
`11 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`
`
`Curriculum Vitae: Gregg, Richard E.
`
`79. Rall, C.J.N., Hoeg, J.M., Gregg, R.E., Law, S.W., Monge, J.C., Meng, M.S., Zech, L.A.,
`and Brewer, H.B., Jr.: Enhanced apolipoprotein E production with normal hepatic
`mRNA levels in the Watanabe Heritable hyperlipidemic rabbit. Arteriosclerosis 8:804-
`809, 1988.
`
`Page 12
`
`
`80. Brewer, H.B., Jr., Gregg, R.E., Hoeg, J.M., and Fojo, S.S.: Apolipoproteins and
`lipoproteins in human plasma: An overview. Clin. Chem. 34:B4-8, 1988.
`
`
`81. Brewer, H.B., Jr., Hoeg, J.M., Beg, Z., Fojo, S.S., and Gregg, R.E.: Translational and
`post-translational processing in apolipoprotein metabolism. In: Agents and Actions
`Suppl 26:133, 1988.
`
`
`82. Brewer, H.B., Jr., Higuchi, K, Hospattankar, A., Hoeg, J., and Gregg, R.E.: Recent
`Advances in the Structure and Biosynthesis of Apolipoproteins B100 and B48.
`Hyperlipidaemia and Atherosclerosis K.E. Suckling and P.H.E. Groot (eds.),
`Academic Press, New York, pp. 33-46, 1988.
`
`
`83. Gregg, R.E., Zech, L.A., Gabelli, C., Brewer, H.B., Jr.: Apolipoprotein E modulates the
`metabolism of apolipoprotein B containing lipoproteins by multiple mechanisms.
`Proceedings of the Second Marburg Conference on Lipoproteins A. Steinmentz and
`H. Kaffarnik (eds.), Springer-Verlag, Heidelberg, pp. 82-92, 1989.
`
`
`84. Benvenga, S., Cahnmann, H.J., Gregg, R.E., and Robbins, J.: Binding of thyroxine to
`low density lipoproteins through specific interactions with apolipoprotein B (apoB-
`100). Biochimie 71:263-268, 1989.
`
`
`85.
`
`Illingworth, D.R., Pappu, A.S., and Gregg, R.E.: Increased urinary mevalonic acid
`excretion in patients with abetalipoproteinemia and homozygous
`hypobetalipoproteinemia. Atherosclerosis 76:21-27, 1989.
`
`
`86. Leitman, S.F., Smith, J.W., and Gregg, R.E.: Homozygous familial
`hypercholesterolemia: Selective removal of low density lipoproteins by secondary
`membrane filtration. Transfusion 29:341-346, 1989.
`
`
`87. Roma, P., Gregg, R.E., Meng, M., Bishop, C., Ronan, R., Zech, L.A., Meng, M.V.,
`Glueck, C., Vergani, C., Franceschini, G., Sirtori, C.R., and Brewer, H.B., Jr.: In vivo
`catabolism of apolipoprotein A-I in subjects with familial hypoalphalipoprotein-emia.
`In: Human Apolipoprotein Mutants 2: From Gene Structure to Phenotypic
`Expression. C.R. Sirtori, G. Franceschini, H.B. Brewer, Jr., and G. Assmann (eds.),
`Plenum Publishing, New York, pp. 51-58, 1989.
`
`
`88. Fojo, S.S., Beisiegel, U., Stalenhoef, A.F.H., Bojanovski, M., Gregg, R.E., Greten, H.,
`and Brewer, H.B., Jr.: The molecular basis of apo C-II deficiency. In: Human
`Apolipoprotein Mutants 2: From Gene Structure to Phenotypic Expression. C.R.
`Sirtori, G. Franceschini, H.B. Brewer, Jr., and G. Assmann (eds.), Plenum Publishing,
`New York, pp. 109-120, 1989.
`
`12 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`
`
`Page 13
`
`Curriculum Vitae: Gregg, Richard E.
`
`89. Gregg, R.E., Roma, P., Bojanovski, D., Schaefer, J.R., Zech, L.A., Kindt, M.R., Meng,
`M.S., Ronan, R., Franceschini, G., Sirtori, C.R., and Brewer, H.B., Jr.: The kinetics of
`apolipoprotein A-I metabolism in humans with altered levels of high density
`lipoproteins. In: Atherosclerosis VIII. G. Crepaldi, A.M. Gotto, E. Manzato, and G.
`Baggio (eds.) Excerpta Medica, Amsterdam, pp. 285-289, 1989.
`
`
`90. Fojo, S.S., Beisiegel, U., Stalenhoef, A.F.H., Gregg, R.E., Greten, H., and Brewer, H.B.,
`Jr.: Genetic defects in apo C-II deficiency. In: Atherosclerosis VIII. G. Crepaldi, A.M.
`Gotto, E. Manzato, and G. Baggio (eds.) Excerpta Medica, Amsterdam, pp. 175-180,
`1989.
`
`
`91. Ross, R.S., Hoeg, J.M., Higuchi, K., Schumacher, U.K., Fojo, S.S., Gregg, R.E., and
`Brewer, H.B., Jr.: Homozygous hypobetalipoproteinemia: transcriptional regulation
`and 5'-flanking sequence analysis in an apolipoprotein B deficiency state. Biochem.
`Biophys. Acta 1004:29-35, 1989.
`
`
`92. Benvenga, S., Cahnmann, H.J., Gregg, R.E., and Robbins, J.: Characterization of the
`binding of thyroxine to high density lipoproteins and apolipoproteins A-I. J. Clin.
`Endocrinol. Metab. 68:1067-1072, 1989.
`
`
`93. Travis, W.D., Davis, G.E., Tsokos, M., Lebovics, R., Merrick, H.F., Miller, S.P., Gregg,
`R.E., DiBisceglie, A.M., Parker, R.I., Ishak, K.G., and Filling-Katz, M.R.: Multifocal
`verruciform xanthoma of the upper aerodigestive tract in a child with a systemic lipid
`storage disease. Am. J. Surg. Pathol. 13:309-316, 1989.
`
`
`94. Banerji, B., Subbaiah, P.V., Gregg, R.E., and Bagdade, J.D.: Molecular species of
`phosphatidylcholine in abetalipoproteinemia: Effect of lecithin-cholesterol
`acyltransferase and lysolecithin acyltransferase. J. Lipid Res. 30:1907-1916, 1989.
`
`
`95. Peters, M.G., Hoffnagle, J.H., McGarvey, C., Fox, I., Gregg, R.E., Jones, E.A.: Primary
`Bilary Cirrhosis: Management of an Unusual Case with Severe Xanthomata by
`Hepatic Transplantation. J. Clin. Gastroenterol. 11:694-697, 1989.
`
`
`96. Mann, W.A., Gregg, R.E., Sprecher, D.L., Brewer, H.B. Jr.: Apolipoprotein E-1
`Harrisburg: A New Variant of Apolitpoprotein E Dominantly Associated with Type
`III Hyperlipoproteinemia. Biochim. Biophys. Acta 1005:239-244, 1989.
`
`
`97. Havel, R.J., Davignon, J., Dujovne, C.A., Gregg, R., Hunninghake, D.B., Miettinen, T.,
`Steinbrecher, U., Tobert, J.A.: AHA Conference Report on Cholesterol Drug Therapy.
`Circulation. 80:744-8, 1989.
`
`
`98. Subbaiah, P.V., Banerji, B., Gregg, R.E., Bagdade, J.D.: Molecular Species of
`Cholesteryl Esters Formed in Abetalipoproteinemia: Effect of Apoprotein B-
`Containing Lipoproteins. J. Lipid Res. 31:927-932, 1990.
`
`
`
`13 of 18
`
`PENN EX. 2055
`CFAD V. UPENN
`IPR2015-01836
`
`

`
`Page 14
`
`Curriculum Vitae: Gregg, Richard E.
`99. Hoeg, J.M., Sviridov, D.D., Tennyson, G.E., Demosky, S.J. Jr., Meng, M.S., Bojanovski,
`D., Safonova, I.G., Repin, V.S., Kuberger, M.B., Smirnov, V.N., Higuchi, K., Gregg,
`R.E., and Brewer, H.B. Jr.: Both Apolipoproteins B-48 and B-100 are Synthesized and
`Secreted by the Human Intestine. J. Lipid Res. 31:1761-1770, 1990.
`
`
`100. Roma, P., Gregg, R.E., Bishop, C., Ronan, R., Zech, L.A., Meng, M.V., Glueck, C.,
`Vergani, C., Giudici, G., and Brewer, H.B. Jr.: Apolipoprotein A-I Metabolism in
`Subjects with a PstI Restriction Fragment Length Polymorphism of the ApoA-I Gene
`and Familial Hypoalphalipoproteinemia. J Lipid Res. 31:1753-1760, 1990.
`
`
`101. Schaeffer, J.R., Rader, D.J., Gregg, R.E., Fairwell, T., Zech, L.A., Kindt, M.R., Benson,
`M.D., Brewer, H.B. Jr.: In vivo protein metabolism utilizing stable isotopes and mass
`spectrometry: a new approach to the study of mutant proteins in humans. Trans.
`Assoc. Am. Physicians. 103:187-194, 1990.
`
`
`102. Filling-Katz, M., Fink, J.K., Oliver, K.L., Kaneski, C., Merrick, H.F., Argoff, C.E.,
`Barton, N., Brady, R.O., Gregg, R.E.: Hyperlipidemia as a complication of Niemann-
`Pick type B disease. Clin. Pediatr. (Phila) 29:670-673, 1990.
`
`
`103. Nichols, W.C., Gregg, R.E., Brewer, H.B. Jr., Benson, M.D.: A mutation in
`apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy.
`Genomics. 8:318-323, 1990.
`
`
`104. Ongkingco, J.R., Mann, W.A., Ruley, E.J., Gregg, R.E.: Severe hyperlipidemia due to
`multiple factors in a child with nephrotic syndrome. Child Nephrol. Urol. 11:107-110,
`1991.
`
`
`105. Alaupovic, P., Knight-Gibson, C., Wang, C.S., Downs, D., Koren, E., Brewer, H.B. Jr.,
`Gregg, R.E.: Isolation and